

Selection of chromosomal DNA libraries using a multiplex CRISPR system

Owen W. Ryan^{1*}, Jeffrey M. Skerker^{1,2,3}, Matthew J. Maurer¹, Xin Li¹, Jordan C. Tsai^{1,4},
Snigdha Poddar¹, Michael E. Lee^{1,2}, Will DeLoache^{1,2}, John E. Dueber^{1,2}, Adam P. Arkin^{1,2,3}
and Jamie H. D. Cate^{1,3,4,5}

¹Energy Biosciences Institute, University of California, Berkeley, CA, USA

²Department of Bioengineering, University of California, Berkeley, CA, USA

³Physical Biosciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA, USA

⁴Department of Molecular and Cell Biology, University of California, Berkeley, CA, USA

⁵Department of Chemistry, University of California, Berkeley, CA, USA

*Current address: BP Biofuels Global Technology Center, San Diego, CA, USA

Correspondence should be addressed to J.H.D.C. (jcate@lbl.gov).

Competing interests statement: A patent application related to this work has been filed by J. Cate and O. Ryan on behalf of the Regents of the University of California.

Abstract

The directed evolution of biomolecules to improve or change their activity is central to many engineering and synthetic biology efforts. However, selecting improved variants from gene libraries in living cells requires plasmid expression systems that suffer from variable copy number effects, or the use of complex marker-dependent chromosomal integration strategies. We developed quantitative gene assembly and DNA library insertion into the *Saccharomyces cerevisiae* genome by optimizing an efficient single-step and marker-free genome editing system using CRISPR-Cas9. With this Multiplex CRISPR (CRISPRm) system, we selected an improved cellobiose utilization pathway in diploid yeast in a single round of mutagenesis and selection, which increased cellobiose fermentation rates by over ten-fold. Mutations recovered in the best cellodextrin transporters reveal synergy between substrate binding and transporter dynamics, and demonstrate the power of CRISPRm to accelerate selection experiments and discoveries of the molecular determinants that enhance biomolecule function.

Introduction

Directed evolution using living systems allows selections for improved biomolecule function to be directly coupled to phenotype. However, present directed evolution systems require the use of extrachromosomal gene libraries encoded in bacteriophage or plasmids, which suffer from high levels of copy number variation (Yokobayashi et al. 2002; Turner 2009; Esvelt et al. 2011). For example, in the yeast *Saccharomyces cerevisiae*, common yeast centromere containing (CEN) plasmids vary widely in copy number per cell resulting in highly variable expression levels from cell to cell (**Figure 1**). Ideally, the selective pressure applied to evolve improved or new biomolecule function should be limited to the DNA sequence level and not to gene copy number in a given cell (Zhou et al. 2012). To overcome copy number variation in yeast, the standard genetic tool of integrating linear DNA into the genome by homologous recombination is too inefficient to insert DNA libraries without multiple steps that rely on dominant selectable markers for chromosomal integrations (Wingler and Cornish 2011) or specialized strain backgrounds (DiCarlo et al. 2013).

Bacterial type II CRISPR-Cas9 genome editing has been used successfully in several eukaryotic organisms (Cong et al. 2013; DiCarlo et al. 2013; Mali et al. 2013; Mali et al. 2013; Shalem et al. 2014) but has not been adapted for selection experiments. Genome editing CRISPR-Cas systems require a Cas9 endonuclease that is targeted to specific DNA sequences by a non-coding single guide RNA (sgRNA) (Jinek, et al. 2012; Jinek et al. 2014). The Cas9-sgRNA ribonucleoprotein complex precisely generates double-strand breaks (DSBs) in eukaryotic genomes at sites specified by a twenty-nucleotide guide sequence at

the 5' end of the sgRNA that base pairs with the protospacer DNA sequence preceding a genomic Protospacer Adjacent Motif (PAM) (Sternberg et al. 2014). The presence of the Cas9-produced DSB in genomic DNA can increase the rate of homology-directed repair (HDR) with linear DNA at the DSB locus by several thousand-fold (Storici et al. 2003; DiCarlo et al. 2013) potentially enabling high-throughput experimental methods. CRISPR-Cas9 could therefore be useful in probing industrial *Saccharomyces cerevisiae* strains, which are more robust compared to laboratory strains (Kerr and Service 2005; Farrell et al. 2006; Rubin 2008), but for which few genetic tools are available, due to the fact that these strains are often polyploid with low-efficiency mating and sporulation.

Results

To optimize the efficiency of HDR in *S. cerevisiae* mediated by Cas9, we first constructed a plasmid expressing *Streptococcus pyogenes* Cas9 fused to a nuclear localization signal (Cas9-NLS) that efficiently localizes to the nucleus of yeast cells (**Figure 2A, B**) (Jinek et al. 2012). We used an intermediate strength promoter, P_{RNR2} , to express Cas9 for genome targeting experiments, because Cas9 (Cas9-NLS-His8x) expression from the P_{RNR2} promoter resulted in yeast strains with near wild type fitness whereas Cas9 expressed using strong yeast promoters such as P_{TDH3} (Lee et al. 2013) reduced yeast fitness relative to wild type cells (**Figure 2C**). Second, we designed a new sgRNA architecture in order to improve its expression and function. Cellular levels of sgRNAs correlate with the efficiency of Cas9-mediated genome targeting in mammalian cells (Hsu et al. 2013). Controlled expression of nuclear-localized RNAs and the correlation between sgRNA levels and Cas9-editing in yeast has not been explored. To better control cellular

levels of correctly folded sgRNA, we developed a modular design by fusing the sgRNA (Mali et al. 2013) to the 3' end of the self-cleaving hepatitis delta virus (HDV) ribozyme (Ke et al. 2007; Webb et al. 2009) (**Figure 2D**). We reasoned that the structured ribozyme would protect the 5' end of the sgRNA from 5' exonucleases (Houseley and Tollervey 2009). Additionally, the HDV ribozyme would cleave the RNA immediately 5' of the ribozyme, removing extraneous RNA sequences and allowing flexibility in which promoters can be used, such as tRNAs whose DNA sequences also serve as RNA polymerase III promoters (Marck et al. 2006). Ribozyme removal of the tRNA would then separate transcription initiation from within the tRNA sequence (Marck et al. 2006) and tRNA nuclear export (Köhler and Hurt 2007) from the process of forming functional sgRNA complexes with Cas9.

To quantify the efficiency and specificity of HDR with the new Cas9/sgRNA format, phenotype screens were performed by the co-transformation of a single plasmid that expresses the Cas9 protein and one or more HDV ribozyme-sgRNAs, containing a 20-nucleotide guide sequence that matches a specific site in the yeast genome, along with a linear double-stranded DNA (**Figure 2E**). The linear dsDNA, which contains a unique 20-mer barcode (Giaever et al. 2002) flanked by common primer sequences and fifty base pairs of DNA homologous to the regions proximal to the PAM motif (**Figure 2F**), acts as a template for DNA repair by HDR, resulting in a unique markerless and barcoded insertion allele. With a single sgRNA, we found tRNA sequences used as RNA polymerase III promoters resulted in nearly 100% efficient barcode insertion in diploid yeast at the *URA3* locus, resulting in 5-fluororotic acid resistance (Boeke et al. 1984) whereas the non-tRNA promoters were mostly ineffective (**Figure 3A** and **Supplementary file 1A**). We also

assessed target sequence bias by targeting 11 unlinked yeast genes in diploid S288C yeast cells using tRNA^{Tyr} as the RNA polymerase III promoter (**Supplementary file 2A**). We found that targeting was highly efficient for every genomic target except *LEU2*, which at first was weak but was restored to 100% by selecting a different guide sequence (*LEU2-2*) as the sgRNA (**Figure 3B**). We also verified that our CRISPR-Cas9/sgRNA system did not result in non-specific genome targeting by sequencing 9 of the targeted strains (**Supplementary file 1B**). We also tested efficacy of our approach in the polyploid industrial *Saccharomyces cerevisiae* strain ATCC4124 that has superior tolerance and productivity phenotypes (Ness et al. 1993). The non-tRNA promoter previously used in haploid yeast (DiCarlo et al. 2013), *P_{SNR52}*, functioned in diploid S288C yeast but failed to result in targeting in the polyploid industrial yeast ATCC4124; in contrast, the tRNA^{Pro} promoter enabled highly-efficient barcode insertion into all copies of the URA3 locus in ATCC4124, which we term *cis*-multiplexing, i.e. introducing a double-stranded DNA break at a single genomic locus across all chromosomes (**Figure 3C** and **Supplementary file 1A**). Notably, tRNA^{Tyr} was inefficient at targeting in ATCC4124 though it was effective in S288C diploid (**Supplementary file 1A**), indicating that the choice of tRNA used for the expression of the HDV-sgRNA impacts multiplexing in a strain-dependent manner.

Since the efficiency of *cis*-multiplexing with our CRISPR-Cas9/sgRNA system is nearly 100% using one sgRNA, we next tested its ability for *trans*-multiplexed CRISPR-Cas9 genome editing, i.e. introducing double-stranded DNA breaks at multiple genomic loci simultaneously, using tRNAs to drive the expression of the HDV-sgRNAs. We simultaneously targeted two and three unlinked genomic loci in diploid cells for loss-of-

function mutagenesis by introducing a single plasmid expressing Cas9 and two or three sgRNAs with two or three gene-specific barcoded DNA molecules, respectively. The efficiency of duplex and triplex targeting (requiring 4 and 6 chromosome cuts, respectively) with two sgRNAs (*URA3* and *LYP1*) or three (*URA3*, *LYP1* and *COX10*) was 43% and 19%, respectively (**Figure 3D** and **Supplementary file 1A**). This multiplexed efficiency was dependent on the presence of the HDV ribozyme 5' of the guide sequence as duplex targeting dropped to 3.5% in cells with sgRNA lacking the 5' HDV ribozyme (**Figure 3D** and **Supplementary file 1A**). We measured the relative cellular abundance of sgRNAs expressed by *P_{SNR52}*, with and without the 5' HDV ribozyme, by reverse transcription quantitative polymerase chain reaction (RT-qPCR) and found that the presence of the ribozyme increases the intracellular abundance of the sgRNAs by six-fold (**Figure 3E**), consistent with the model that sgRNA abundance is rate limiting for CRISPR/Cas targeting (Hsu et al. 2013). Haploid *trans*-multiplexing showed a minimal loss in activity scaling from one to three loci (up to three chromosome cuts) (**Figure 3F** and **Supplementary file 1A**). These experiments demonstrate that our multiplexed CRISPR/Cas9 system, which we term CRISPRm, is powerful enough to generate multiple marker-free targeted mutations in the yeast genome in a single experiment and that the 5' tRNA-HDV ribozyme sequence is required for higher order multiplex targeting.

Having established CRISPRm for *cis*- and *trans*-multiplex targeting, we next tested its capabilities in engineering genes and pathways integrated in the yeast genome. We first tested whether CRISPRm could be used to assemble foreign genes as chromosomal integrations. We tested the efficiency of *in vivo* assembly of a functional nourseothricin-

resistance (Nat^R) gene from three overlapping PCR products encoding a transcription promoter, protein open reading frame (ORF) and transcription terminator at a single locus using *cis*-multiplexing in the diploid S288C strain. The efficiency of Cas9-mediated integration and assembly of these three DNA fragments to the correct (*URA3*) locus was measured by a combination of 5-fluoroorotic acid resistance (5-FOA^R) and Nat^R. We found 85% efficiency of targeting and assembly in both copies of the *URA3* locus in diploid yeast S288C cells, and 70% in polyploid ATCC4124 by using the tRNA^{Pro} sequence as the sgRNA promoter (**Figure 3C** and **Supplementary file 1A**), whereas *P_{SNR52}*-dependent targeting was weaker in S288C cells and non-existent in ATCC4124 cells (**Figure 3C** and **Supplementary file 1A**). Thus, CRISPRm enables the one-step markerless assembly of functional genes from multiple fragments into the *S. cerevisiae* genome, resulting in homozygous insertions into both diploid and polyploid yeast strains.

Finally, we tested whether CRISPRm could be used for *in vivo* selections of improved protein function. We targeted a cellodextrin utilization pathway from the cellulolytic fungus *Neurospora crassa*, comprised of the cellodextrin transporter (*cdt-1*) and an intracellular β -glucosidase (*gh1-1*), to assemble *in vivo* in diploid *S. cerevisiae*. In combination, these two genes result in yeast cells capable of consuming the disaccharide cellobiose, which could be used to improve biofuel production (Galazka, et al. 2010). To select for improved cellobiose utilizing strains we used error-prone PCR to amplify the *cdt-1* gene. We co-transformed the library of mutated *cdt-1* alleles, along with overlapping dsDNA fragments for the promoter and terminator, for assembly and integration into the *URA3* locus (*ura3::P_{PGK1}-cdt-1-T_{ADH1}* library) of a diploid strain with a previously integrated

176 β -glucosidase *gh1-1* gene (*lyp1::P_{TDH3}-gh1-1-T_{CYC1}*) using CRISPRm. We then grew the
177 transformants in medium containing cellobiose as the sole carbon source to select for
178 functional *cdt-1* alleles and identified one strain with 2.6-fold (homozygous *cdt-1*
179 N209S/I354N/S360P/T406S/W531L allele) and one strain with 1.7-fold (homozygous *cdt-1*
180 1 Q45H/F262Y/F533Y allele) increased cellobiose utilization capacity over wild type *cdt-1*
181 (**Figure 4A**). The mutations were mapped in CDT-1 onto structures of the homologous
182 major facilitator superfamily (MFS) hexose-like transporters XylE from *Escherichia coli*
183 (Sun et al. 2012) and GlcP from *Staphylococcus epidermidis* (Iancu et al. 2013)(**Figure 4B**).
184 Notably, one site maps to a site that likely interacts directly with the sugar substrate
185 (N209S)(**Figure 4B**). Whereas two mutations in the 2nd allele (Q45H, F533Y) map to non-
186 conserved regions of the transporters, one (F262Y) maps to a site immediately adjacent to
187 the nearly universally-conserved PESPR motif in hexose transporters that is involved in
188 transporter dynamics (Sun et al. 2012). Furthermore, the mutation from phenylalanine to
189 tyrosine results in an expanded motif (PESPRY) that is present in all of the major hexose
190 transporters in *Saccharomyces cerevisiae* (**Figure 4B**). We then used CRISPRm to introduce
191 the N209S mutation (nucleotide G626A) in the *cdt-1*^{Q45H/F262Y/F533Y} diploid yeast background.
192 The quadruple mutant *cdt-1* allele resulted in synergistic cellobiose utilization with 3.9-fold
193 increased growth over strains expressing wild-type *cdt-1* (**Figure 4A**). We next tested the
194 selected *cdt-1* alleles in anaerobic fermentations using cellobiose as the sole carbon source.
195 We constructed a *cdt-1*^{N209S/F262Y} double-mutant in diploid yeast using CRISPRm, and
196 compared it to wild-type *cdt-1* and the *cdt-1*^{Q45H/N209S/F262Y/F533Y} quadruple mutant. We
197 found that wild-type *cdt-1* integrated into the chromosome was barely able to support
198 cellobiose fermentation (**Figure 4C**). By contrast, the *cdt-1*^{Q45H/N209S/F262Y/F533Y} quadruple

mutant or the *cdt-1*^{N209S/F262Y} double-mutant expressed from the chromosome resulted in complete fermentation of cellobiose, comparable to wild-type *cdt-1* expressed from a high-copy 2μ plasmid (**Figure 4C**) (Ha et al. 2011).

Discussion

We have demonstrated that CRISPRm can be used to quickly generate markerless loss-of-function alleles, heterologous insertion alleles, allele swaps and engineer proteins in yeast by *in vivo* selections for greatly improved metabolic activity. Although we selected for improved protein function, as suggested by the location of the mutations in CDT-1 (**Figure 4B**), it is also possible that selection enriched for sequences that confer improved mRNA stability or translation efficiency, due to the fact that the selection was carried out *in vivo*. Future experiments will be needed to distinguish between these possibilities.

CRISPRm could be used to integrate DNA libraries to interrogate *cis*-regulatory elements such as transcription promoters, 5'- and 3'-untranslated regions (5'-UTRs and 3'-UTRs) in mRNAs, or riboswitches. CRISPRm enables these types of experiments because it allows for near quantitative integration of DNA libraries, which can be a single fragment or complex assemblies of multiple fragments. This could enable integration and selection of multi-gene pathways, or specific mutation and selection of subsets of a protein or multiple DNA-encoded functions.

The ability to use chromosomally-integrated DNA libraries removes a key limitation in *in vivo* selection experiments by eliminating biomolecule expression variation due to

variable plasmid copy numbers. Although we used a relatively small library size in the present experiments, even in this small library we observed impressive gains in transporter function. We observed 2-3 mutations per kilobase in the selected transporter genes, resulting in 3-5 amino acid substitutions per transporter. We were then able to combine the mutations in a single transporter with superior fermentation performance. Library sizes introduced by CRISPRm should be scalable to the limits of transformation efficiency, to 10^7 or larger (Kawai et al. 2010). CRISPRm should also enable multiple rounds of selection for directed evolution experiments. We envision that each cycle would involve error-prone PCR of the gene of interest, either from a starting sequence or an enriched and improved cell population, followed by CRISPRm-mediated integration of the amplified gene and selection. This cycle would compare favorably with that required for plasmid-based selections, yet would avoid the problem of plasmid copy number variation. CRISPRm should also be adaptable to screens that rely on sorting large populations of cells, i.e. by fluorescence-activated cell sorting. We envision that CRISPRm could improve the discovery of human therapeutics by yeast display (Krugel et al. 1988), and could be used to map the importance of protein-protein interactions (Ovchinnikov et al. 2014) via multiplexed library insertion.

To achieve high efficiency multiplexing with CRISPRm, we found it was necessary to modify the sgRNA design by including a 5' HDV ribozyme, and to assay multiple RNA polymerase III promoters for a given strain background. The ease of discovering tRNAs in any genome and the universality of the sgRNA construct means that, with few modifications, CRISPRm can be used directly in non-model fungal hosts, such as pathogens

or organisms used in the biotechnology industry. The genetics of many of these organisms have not been studied in any depth due to the technological limitations of available genetic manipulation techniques. For example, industrial *Saccharomyces cerevisiae* strains are more stress tolerant and produce much higher yields of desired biofuel or renewable chemical end products than laboratory strains (Kerr and Service 2005; Farrell et al. 2006; Rubin 2008). However, linking genotypes of industrial yeasts to their phenotypes remains difficult. CRISPRm should serve as a rapid and high throughput means for connecting the genotypes of these organisms to their phenotypes, i.e. for generating marker-free barcoded alleles for large-scale pooled fitness studies of loss-of-function mutants in these organisms (Giaever et al. 2002). In the future, CRISPRm may also be applicable to interrogating mammalian cells, if the levels of HDR are sufficiently high. Finally, the ability to use CRISPRm for multiplexed targeting paves the way for applying directed evolution to cellular pathways and genetic circuits for higher order synthetic biology applications in any host strain.

Materials and Methods

Cloning the pCAS plasmid backbone

Gibson Assembly Mastermix (E2611L)(New England Biolabs, Ipswich, MA) (Gibson et al. 2009) was used to fuse the KANMX (Yeastdeletionpages.com) cassette to the pUC bacterial origin of replication from pESC-URA (Agilent Technologies, Santa Clara, CA). Restriction – free (RF)(van den Ent and Lowe 2006) cloning was used to add a yeast 2 μ origin of replication from pESC-URA to the pCAS backbone. The resulting pCAS backbone plasmid was propagated in yeast to confirm functionality.

Cas9 expression constructs

The Cas9 gene from *Streptococcus pyogenes* was amplified from clone MJ824 (Jinek et al. 2012) and cloned into the pCAS backbone plasmid by RF cloning. A yeast nuclear localization signal (NLS) sequence, codon optimized using IDT software (Integrated DNA Technologies, Coralville, IO), was then cloned into the plasmid by RF cloning. Additional elements fused by RF cloning to the Cas9-NLS sequence included the GFP gene, the CYC1 terminator from *S. cerevisiae* strain S288c (Yeastgenome.org) and the promoters (800 base pairs upstream) from the genes *TDH3*, *TEF1*, *RNR2* and *REV1*, also taken from strain S288c (Lee et al. 2013). For genome editing experiments, the GFP sequence was removed from the Cas9 gene and replaced with a C-terminal His₈ affinity tag, by RF cloning.

Engineering of sgRNA constructs

Synthetic DNA (Integrated DNA Technologies, Coralville, IO) for the sgRNA and for a catalytically active form of the Hepatitis Delta Virus (HDV) Ribozyme was sequentially

cloned by RF cloning into the Cas9 containing vector (pCAS). The terminator (200bp) of *SNR52* (Yeastgenome.org) was cloned 3' of the ribozyme-sgRNA sequence by RF cloning. A series of RNA polymerase III (Pol III) promoters were PCR amplified from S288c genomic DNA and cloned 5' of the ribozyme-sgRNA sequence by RF cloning. The tRNA promoters included the full-length tRNA plus 100 base pairs upstream of the tRNA gene (**Supplementary file 1C**). The sgRNAs used for multiplex targeting were PCR amplified using primers containing 5' and 3' restriction sequences and sub-cloned into pCAS by ligation dependent cloning into Sall, SpeI and SacII unique restriction sites.

Yeast strains used in this study

S. cerevisiae strain S288c (ATCC 204508) was used as the haploid, and then mated to form the homozygous diploid for the diploid experiments. Yeast strain ATCC4124 is an industrial polyploid yeast isolated from a molasses distillery, and was obtained from ATCC.

Cas9-GFP Localization and Expression

Expression and localization of Cas9-GFP was verified by imaging haploid *S. cerevisiae* S288c cells transformed with pCas9-GFP::KAN using fluorescence microscopy (Leica Epifluorescence, Leica Microsystems, Buffalo Grove, IL). Cells were grown overnight and nuclear localization visualized at 100X magnification.

Fitness analysis of Cas9 expressed by different promoters

Yeast cells containing pCAS (Cas9-His₈ variant) were grown in a Bioscreen C Growth Curve Analyzer (Growth Curve USA, Piscataway, NJ) in 200 µL of YPD + G418 liquid

medium (20 g/L Peptone (Bacto 211667), 10 g/L Yeast Extract (Bacto 212750), 0.15 g/L Adenine hemisulfate (Sigma A9126) and 20 g/L Glucose (Sigma G8270) + 200 mg/L G418 (Santa Cruz Biotechnology 29065A)). Cells were grown in three biological replicates each with five technical replicates for 48 hours at 30 °C under constant shaking. The wild-type control containing an empty vector (pOR1.1) was also grown in five technical replicates. Mean and standard deviations of the optical density at 600 nm were calculated for each time point measured by the Bioscreen.

CRISPR-Cas9 Screening Protocol

The Cas9 transformation mix consisted of 90 µL yeast competent cell mix (OD₆₀₀=1.0), 10.0 µL x10mg/mL ssDNA (Sigma D9156, St. Louis, MO), 1.0 µg pCAS plasmid, 5.0 µg of linear repair DNA and 900 µL Polyethyleneglycol₂₀₀₀ (Sigma 295906), 0.1M Lithium acetate (Sigma 517992) 0.05M Tris-HCl (Invitrogen 155568) EDTA (Fisher Scientific 10618973). To measure Cas9 independent integration, the linear DNA was co-transformed with a plasmid lacking the Cas9 protein and sgRNA (pOR1.1) (**Supplementary file 2B**). Cells were incubated 30 minutes at 30 °C, and then subjected to heat shock at 42 °C for 17 minutes. Following heat shock, cells were re-suspended in 250 µL YPD at 30 °C for two hours and then the entire contents were plated onto YPD+G418 plates (20 g/L Peptone, 10 g/L Yeast Extract, 20 g/L Agar, 0.15 g/L Adenine hemisulfate, 20 g/L Glucose and G418 at 200 mg/L). Cells were grown for 48 hours at 37 °C, and colonies imaged using the Biorad ChemiDoc Imager (Biorad, Hercules, CA) before replica plating onto phenotype-selective media. The guide sequences in the sgRNAs used for targeting the various loci are shown in **Supplementary file 1D**. *URA3* mutants were selected on 2.0 g/L

330 Yeast nitrogen base without amino acids or ammonium sulfate (Sigma Y1251), 5.0 g/L
331 Ammonium sulfate (Sigma A4418), 1.0 g/L CSM (MP Biosciences 4500-012), 20 g/L
332 Glucose, 20 g/L Agar + 5-fluoroorotic acid (1g/L) (Goldbio F-230-25); *LYP1* mutants were
333 selected on 2.0 g/L Yeast nitrogen base without amino acids or ammonium sulfate, 5.0 g/L
334 Ammonium sulfate, 1.0 g/L CSM-lysine (MP Biosciences 4510-612), 20 g/L Glucose, 20 g/L
335 Agar + thialysine (100mg/L) (Sigma A2636); *CAN1* mutants were selected on 2.0 g/L Yeast
336 nitrogen base without amino acids or ammonium sulfate, 5.0 g/L Ammonium sulfate, 1.0
337 g/L CSM-arginine (MP Biosciences 4510-112), 20 g/L Glucose, 20 g/L Agar + canavanine
338 sulfate (50mg/L) (Sigma C9758); the remaining auxotrophic mutants were selected on
339 2.0g/L Yeast nitrogen base without amino acids or ammonium sulfate, 5.0 g/L Ammonium
340 sulfate, 1.0 g/L CSM , 20 g/L Glucose, 20 g/L Agar; and aerobic respiration deficient
341 mutants (*petites*) were selected on 20 g/L Peptone, 10 g/L Yeast Extract, 20 g/L Agar, 0.15
342 g/L Adenine hemisulfate, 20 g/L Glycerol (Sigma G5516). Colonies from the YPD+G418
343 plates were picked and grown overnight in 0.8mL of YPD. Genomic DNA was extracted
344 from these cultures using the MasterPure Yeast DNA Extraction Kit (Epicentre MPY80200).
345 PCR confirmation of the 60-mer integration allele was performed using primers flanking
346 the target site. PCR products were purified by Exo-SAP-IT (Affymetrix 78201) and Sanger
347 sequenced at the UC Berkeley, Sequencing Facility (Berkeley, CA) to confirm barcode
348 sequence in the amplicon.

349

350 *RT-qPCR of sgRNAs*

351 Cells containing the pCAS plasmid with sgRNA inserts were grown in 900 μ L of
352 YPD+G418 medium for 24 hours at 30 °C and 750 rpm. Total RNA was extracted from

exponentially growing yeast cells using Ambion RNA RiboPure™ Yeast Kit (AM1926)(Life Technologies, Carlsbad, CA). RT-qPCR was performed on the Applied Biosciences StepOne™ Real-Time PCR System (Applied Biosystems, Foster City, CA) using the Invitrogen EXPRESS One-Step SYBR® GreenER™ Kit (Life Technologies, Carlsbad, CA). The RT-qPCR expression level data was quantified using the Comparative C_T ($\Delta\Delta C_T$) method and relative abundance of the sgRNA was normalized to the mRNA transcript *UBC6*, which was used as the endogenous control (Teste et al. 2009). The primer sequence used for the RT reaction was 5'-AAAAGCACCGACTCGGT-3' and the additional q-PCR primer used was 5'-GTTTTAGAGCTAGAAATAGCAAG-3'. The primers used for the *UBC6* endogenous control were (RT) 5'-CATTTTCATAAAAAGGCCAACC-3' and (qPCR) 5'-CCTAATGATAGTTCTTCAATGG-3'. DNA sequences for the sgRNAs used to test HDV ribozyme function are shown in **Supplementary file 2C** and **Supplementary file 2D**.

Multiplex genome targeting by Cas9

Multiplex targeting was performed as described above using pCAS plasmids containing more than one sgRNA expression construct cloned into one of the restriction sites by ligation dependent cloning. Single versus double mutant efficiency was scored relative to the number of colonies present on the YPD+G418 plate. Genomic DNA isolation and PCR of the integration site was performed as described above.

Multiplex in vivo assembly of DNA using Cas9

Drug resistance cassettes were assembled *in vivo* from three linear double-stranded DNA fragments PCR amplified from the *Ashbya gossypii* *TEF1* promoter (*AgP_{TEF1}*), the

376 nourseothricin open reading frame (Nat^R) and *Ashbya gossypii* *TEF1* (*AgT_{TEF1}*) terminator
377 in separate reactions. The primers used to amplify the promoter and terminators
378 contained 50 bp of homology to the nourseothricin ORF and 50 bp of homology to the
379 genomic target. Colonies exhibiting drug resistance (nourseothricin 100 mg/L) (Goldbio N-
380 500-1) following replica plating were compared to the number of colonies on the
381 YPD+G418 to determine efficiency of multiplex assembly.

382

383 *Selection of improved variants of cellodextrin transporter CDT1*

384 To generate *CDT1* mutant allele libraries, the GeneMorph II Random Mutagenesis
385 Kit (Aglient 200550)(Agilent Technologies, Santa Clara, CA) was used to amplify the *N.*
386 *crassa cdt-1* open reading frame. The library of *cdt-1* mutant alleles was co-transformed
387 with PCR-amplified linear dsDNA fragments encoding the *ScP_{PGK1}* promoter and *ScT_{ADH1}*
388 terminator into a diploid S288c yeast strain containing a previously-integrated *gh1-1* gene.
389 The *gh1-1* gene included the *ScP_{TDH3}* promoter, the *N. crassa gh1-1* open reading frame and
390 *ScT_{CYC1}* terminator. The primers used to amplify the promoters and terminators contained
391 50 bp of homology to either the *cdt-1* or *gh1-1* ORFs and 50 bp of homology to the
392 respective the genomic targets. Five µg of each of the three PCR products (promoter, open
393 reading frame, terminator) were co-transformed with the pCAS plasmid containing the
394 *URA3* guide sequences and screened for G418 resistance as described. Approximately 1600
395 G418-resistant colonies were pooled and resuspended in minimal cellobiose medium
396 (SCel) (2.0g/L Yeast nitrogen base without amino acids or ammonium sulfate, 5.0 g/L
397 Ammonium sulfate, 1.0 g/L CSM , 20 g/L Cellobiose). Resuspended cells were immediately
398 spread evenly on SCel plates for initial analysis prior to cellobiose selection (*t*=0 samples).

Ten microliters of the resuspended cells were inoculated in 50 mL of SC medium in biological triplicate. Cells were harvested after three days and spread onto SCel plates. Cells were grown at 30 °C for four days, and the largest colonies were chosen for further analysis.

Tecan growth analyzer and fitness calculation of cdt-1 alleles

Cells were grown overnight in 0.5 mL of Synthetic Dextrose (2%) (SD) in 96 well plates. Cultures were diluted 1:500 in SCel media (4% cellobiose) and 150 µL were grown using the Tecan Sunrise (Tecan Systems Inc., San Jose, CA) in biological triplicate for three days at 30 °C. Average and standard deviation was calculated for each biological sample. Relative fitness was calculated by measuring area between the curves (ABC) which normalizes growth to the area under the curve (AUC) for diploid cells lacking *cdt-1* ($ABC = AUC\ cdt-1^+ - AUC\ cdt-1^-$). Fold cellobiose utilization capacity = $(ABC\ cdt-1^{S209}/ABC\ cdt-1^-)$.

Generating the double mutant and quadruple cdt-1 alleles

Integration of the repair oligonucleotide into the chromosomal wild-type *cdt-1* gene or *cdt-1*^{Q45H/F262Y/F533Y} was performed as described for integrating barcoded DNA. The sgRNA sequence used to target the wild type allele of *cdt-1* was cloned into the pCAS vector with the sequence 5'-TGCACTGGCTTCTACAACTG-3'. The repair oligonucleotide used to make the A626G (i.e. N209S) mutation was 5'-CGGCCGCTGCACTGGCTTCTACAGCTGCGGTTGGTTCGGAGGTTTCATTCCTGCCGCCTG-3' with fifty more base pairs of homology to *cdt-1*, on both sides of the above oligonucleotide. Genomic DNA was extracted as described and Sanger sequencing confirmed the

incorporation of the A626G mutation. Similarly, the T785A mutation (F262Y) was incorporated into the *cdt-1*^{N209S} allele using an sgRNA with guide sequence 5'-CCTCGCTTCCTATTTGCCAA-3', and a repair oligonucleotide with sequence 5'-AGAATCCCCTCGCTACCTATTTGCCAACGGCCGCGACGCTGAGGCTGTTGCCTTTCTTGT-3'. Genomic DNA was extracted as described and Sanger sequencing confirmed the incorporation of the T785A mutation.

Structural analysis of cdt-1^{N209S/Q45H/F262Y/F533Y}

The sequences of *N. crassa* CDT-1 (accession XP_963801), *Escherichia coli* XlyE (accession YP_492174.1), and *Staphylococcus epidermidis* GlcP glucose transporter (accession ZP_04818045.1) were aligned with the MUSCLE algorithm (Edgar 2004). Figures were prepared with the PyMol molecular graphics system (<http://www.pymol.org/>).

Imaging of integrated and plasmid based fluorescent proteins

Strain yML068 was generated by integrating a short DNA “spacer” sequence and Leu2 into the *LEU2* locus of BY4741. Strain yML069 was generated by integrating *P_{TDH3}-mRuby2-T_{TDH1}* and Ura3 into the *URA3* locus, and integrating *P_{TDH3}-Venus-T_{TDH1}* and Leu2 into the *LEU2* locus of BY4741. Strain yML104 was generated by integrating *P_{TDH3}-mRuby2-T_{TDH1}-P_{TDH3}-Venus-T_{TDH1}* and Ura3 into the *URA3* locus of yML068. Plasmid pML1350 is a Ura3 CEN6/ARS4 plasmid with *P_{TDH3}-mRuby2-T_{TDH1}*. pML1362 is a Leu2 CEN6/ARS4 plasmid with *P_{TDH3}-Venus-T_{TDH1}*. pML1177 is a Ura3 CEN6/ARS4 plasmid with *P_{TDH3}-mRuby2-T_{TDH1}-P_{TDH3}-Venus-T_{TDH1}*.

Synthetic defined media lacking leucine and uracil (SD-LU) was made by adding 6.7 g/L Difco Yeast Nitrogen Base without amino acids; 2 g/L Drop-out Mix Synthetic Minus Leucine, Uracil without Yeast Nitrogen Base (US Biological); and 20 g/L Dextrose to distilled water.

Colonies were picked into SD-LU media and grown to exponential phase at 30 °C. Cultures were concentrated by centrifugation, spotted onto plain glass slides, and examined on a Zeiss Observer D1 microscope using a 100x DIC objective. Images were captured using a Hamamatsu Orca-flash 4.0 (C11440) camera using auto-exposure. Fluorescence images were taken using an X-Cite Series 120 lamp, Zeiss filter set (excitation at 560/40 nm and emission at 630/75 nm) for mRuby2, and Zeiss filter set (excitation at 500/20 nm and emission at 535/30 nm) for Venus. Images were analyzed and composites were created using Fiji (<http://fiji.sc>).

Illumina sequencing to identify potential off-target mutations

To rule out that our CRISPR-Cas9/sgRNA system resulted in non-specific genome targeting, we performed whole genome sequencing for *URA3* and *LYP1* targeted strains and searched for insertion/deletions (INDELs), single nucleotide polymorphisms (SNPs) and multi-nucleotide polymorphisms (MNP). We identified 21 sequence variants across the nine *URA3* and *LYP1* targeted strains (**Supplementary file 1B**). Whole genome sequencing was performed by the UC Davis Genome Center (Davis, CA) using the Illumina MiSeq platform (Illumina, Hayward, CA) to produce 150 bp paired-end reads. The software

package versions used for sequencing data analysis were as follows: BWA (v. 0.7.5a-r405), Picard (v. 1.92(1464)), SAMtools (v. 0.1.19-44428cd) and the GATK (2.7-2-g6bda569). The S288C reference genome (v. R64-1-1, release date Feb 3, 2011) was obtained from the *Saccharomyces* Genome Database (yeastgenome.org) and prepared for use in sequencing data analysis with bwa index, CreateSequenceDictionary from Picard, and samtools faidx. Sequencing reads were processed with Scythe (v. 0.991) to remove adapter contamination and Sickle (v. 1.210) to trim low quality bases. Processed reads were mapped to the S288C reference genome using bwa mem with the -M option for picard and GATK compatibility. The mapped reads were sorted with SortSam and duplicate reads were marked with MarkDuplicates from Picard. Read alignments were refined by performing local realignment with the RealignerTargetCreator and IndelRealigner walkers from the GATK on all samples collectively.

Variant detection for both SNPs and INDELs was performed with GATK's UnifiedGenotyper, with parameters adjusted for haploid genomes and no downsampling of coverage, for each sample independently. The resulting SNP and INDEL calls were filtered with the VariantFiltration walker from GATK (see header of the VCF file, supplemental VCF file, for details). A custom Perl script (**Supplementary file 3**) was written to identify all GG dinucleotide sequences in the S288C reference genome, extract every Cas9 target sequence (i.e. 20nt sequence corresponding to the 20 nucleotides immediately 5' of the "NGG" PAM site), and obtain the genome coordinates ranging from 30 nucleotides upstream and downstream of the PAM site. Cas9 target sequences were added to VCF files as custom annotations using snpEff (v3.3h), and SnpSift (v3.3h) was used to extract desired fields into

tables for analysis with a custom R script (**Supplementary file 4**). Needleman–Wunsch global alignments between our guide sequences and Cas9 target sequences were performed using the pairwiseAlignment function (Biostrings package, Bioconductor) in R, with a substitution matrix of -1 for mismatches and 2 for matches, produced with the nucleotideSubstitutionMatrix function (Biostrings package, Bioconductor). The probability of there being a better match for the guide sequence to a given Cas9 target sequence was calculated as the frequency of Cas9 target sequences with better alignments to the same guide sequence, amongst 10,000 randomly selected Cas9 target sequences. To compile counts of all variants and various subclasses, a GATKReport was generated from the VCF files with GATK’s VariantEval walker, read into R using the “gsalib” library, and the desired categories were extracted with a custom R script (**Supplementary file 4**).

Without the repair DNA template required for HDR, the majority of mutations caused by Cas9 are expected to be INDELs, SNPs or MNPs that initiate within the protospacer sequence, which is the 20 nucleotide (nt) sequence 5’ of the PAM (Fu et al. 2013). Therefore, for completeness, we searched for all PAM sites within 30 nt upstream and downstream for each of the 21 variants. We then compared the 20 nt *URA3* and *LYP1* guide sequences to the putative protospacer sequences within the regions flanking each variant. An end-to-end alignment identified 10 or fewer nucleotide matches between the *URA3* or *LYP1* guide sequences and the variant sequences (**Supplementary file 1B**). Cas9 requires at least 12 perfect base pair matches within the guide-target sequence (Hsu, Scott et al. 2013) so it is highly unlikely that the *URA3* and *LYP1* guide sequences directed Cas9 to

any of these potential protospacers that lie within variant sites. These mutations likely arose as natural variants during the course of the experiment.

As a second method to evaluate the likelihood of off-target mutations, we performed local alignments of our guide sequences to all Cas9 target sequences whose PAM site was within 30 nucleotides upstream and downstream of a detected variant, as well as to 10,000 randomly selected Cas9 target sequences from the genome. Since our guide sequences are expected to have a better match to 13% or more of all Cas9 target sequences (~126,000 or more sites) than to the best matching Cas9 target sequence with a nearby variant, and the number of nucleotide matches in end-to-end alignments is at most 10, we argue that the variants identified in the genomes of *URA3*- and *LYP1*-targeted strains are unlikely the result of off-target Cas9 modifications.

Anaerobic Fermentations

Yeast strain colonies were inoculated in 20 mL of oMM (optimized minimal media) (Yuping Lin, personal communication) with 2% glucose in 50 mL Falcon tubes and grown aerobically at 30 °C to saturation for 24 hours. The oMM contained 1.7 g/L YNB (Y1251, Sigma, Saint Louis, MO, USA), 2X CSM, 10 g/L (NH₄)₂SO₄, 1 g/L MgSO₄·7H₂O, 6 g/L KH₂PO₄, 100 mg/L adenine hemisulfate, 10 mg/L inositol, 100 mg/L glutamic acid, 20 mg/L lysine, 375 mg/L serine and 0.1 M 2-(*N*-morpholino) ethanesulfonic acid (MES) pH 6.0. The saturated cultures were then inoculated to starting OD₆₀₀ of 0.2 in 500 mL of oMM with 2% glucose in 1 L Erlenmeyer flasks and grown aerobically at 30 °C to mid-log phase at a final OD₆₀₀ of 2.5. Cells were harvested and washed twice with sterile ddH₂O. The washed

cells were then inoculated at OD₆₀₀ of 20 in 50 mL oMM with 1% glucose and 8% cellobiose in 125 mL serum flasks. After inoculation, the flasks were sealed with rubber stoppers and clamped with an aluminum seal. To achieve anaerobic conditions, the headspaces of the sealed flasks were purged with nitrogen gas for 30 minutes. These were then cultivated at 30 °C and 220 rpm.

Using sterile needles and syringes, 1 mL samples were removed through the rubber stoppers at the indicated time points. The cells were pelleted and 5 µL of the supernatants were analyzed for cellobiose, glucose, glycerol, and ethanol content by high performance liquid chromatography on a Prominence HPLC (Shimadzu, Kyoto, Japan) equipped with Rezex RFQ-FastAcid H 10 × 7.8 mm column. The column was eluted with 0.01 N of H₂SO₄ at a flow rate of 1 mL/min, 55 °C.

Acknowledgments

We thank D. Nunn and J. Doudna for helpful discussions. We thank J. Waters for assistance in phenotype screening assays. This work was supported by funding from the Energy Biosciences Institute.

References

- Boeke, J. D., F. LaCroute and G. R. Fink. (1984). "A positive selection for mutants lacking orotidine-5'-phosphate decarboxylase activity in yeast: 5-fluoro-orotic acid resistance." Mol Gen Genet **197**(2): 345-346.
- Cong, L., F. A. Ran, D. Cox, S. Lin, R. Barretto, N. Habib, P. D. Hsu, X Wu, W. Jiang, L. A. Marraffini and F. Zhang. (2013). "Multiplex genome engineering using CRISPR/Cas systems." Science **339**(6121): 819-823.

DiCarlo, J. E., A. J. Conley, M. Penttilä, J. Jäntti, H. H. Wang and G. M. Church. (2013). "Yeast Oligo-Mediated Genome Engineering (YOGE)." ACS Synth Biol **2**(12): 741-749.

DiCarlo, J. E., J. E. Norville, P. Mali, X. Rios, J. Aach and G. M. Church. (2013). "Genome engineering in *Saccharomyces cerevisiae* using CRISPR-Cas systems." Nucleic Acids Res **41**(7): 4336-4343.

Edgar, R. C. (2004). "MUSCLE: multiple sequence alignment with high accuracy and high throughput." Nucleic Acids Res **32**(5): 1792-1797.

Esvelt, K. M., J. C. Carlson, and D. R. Liu. (2011). "A system for the continuous directed evolution of biomolecules." Nature **472**(7344): 499-503.

Farrell, A. E., R. J. Plevin, B. T. Turner, A. D. Jones, M. O'Hare and D. M. Kammen. (2006). "Ethanol can contribute to energy and environmental goals." Science **311**(5760): 506-508.

Fu, Y., J. A. Foden, C. Khayter, M. L. Maeder, D. Reyon, J. K. Joung and J. D. Sander. (2013). "High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells." Nat Biotechnol **31**(9): 822-826.

Galazka, J. M., C. Tian, W. T. Beeson IV, B. Martinez, N. L. Glass and J. H. Cate. (2010). "Cellodextrin transport in yeast for improved biofuel production." Science **330**(6000): 84-86.

Giaever, G., A. M. Chu, L. Ni, C. Connelly, L. Riles, S. Véronneau, S. Dow, A. Lucau-Danila, K. Anderson, B. André, A. P. Arkin, A. Astromoff, M. El-Bakkoury, R. Bangham, R. Benito, S. Brachat, S. Campanaro, M. Curtiss, K. Davis, A. Deutschbauer, K. D. Entian, P. Flaherty, F. Foury, D. J. Garfinkel, M. Gerstein, D. Gotte, U. Güldener, J. H. Hegemann, S. Hempel, Z. Herman, D. F. Jaramillo, D. E. Kelly, S. L. Kelly, P. Kötter, D. LaBonte, D. C. Lamb, N. Lan, H. Liang, H. Liao, L. Liu, C. Luo, M. Lussier, R. Mao, P. Menard, S. L. Ooi, J. L. Revuelta, C. J. Roberts, M. Rose, P. Ross-Macdonald, B. Scherens, G. Schimmack, B. Shafer, D. D. Shoemaker, S. Sookhai-Mahadeo, R. K. Storms, J. N. Strathern, G. Valle, M. Voet, G. Volckaert, C. Y. Wang, T. R. Ward, J. Wilhelmy, E. A. Winzeler, Y. Yang, G. Yen, E. Youngman, K. Yu, H. Bussey, J. D. Boeke, M. Snyder, P. Philippsen, R. W. Davis and M. Johnston. (2002). "Functional profiling of the *Saccharomyces cerevisiae* genome." Nature **418**(6896): 387-391.

Gibson, D. G., L. Young, R. Y. Chuang, J. C. Venter, C. A. Hutchison III and H. O. Smith. (2009). "Enzymatic assembly of DNA molecules up to several hundred kilobases."

Ha, S. J., J. M. Galazka, S. R. Kim, J. H. Choi, X. Yang, J. H. Seo, N. L. Glass, J. H. Cate and Y. S. Jin. (2011). "Engineered *Saccharomyces cerevisiae* capable of simultaneous cellobiose and xylose fermentation." Proc Natl Acad Sci U S A **108**(2): 504-509.

Houseley, J. and D. Tollervey (2009). "The many pathways of RNA degradation." Cell **136**(4): 763-776.

Hsu, P. D., D. A. Scott, J. A. Weinstein, F. A. Ran, S. Konermann, V. Agarwala, Y. Li, E. J. Fine, X. Wu, O. Shalem, T. J. Cradick, L. A. Marraffini, G. Bao and F. Zhang. (2013). "DNA targeting specificity of RNA-guided Cas9 nucleases." Nat Biotechnol **31**(9): 827-832.

Iancu, C. V., J. Zamoon, S. B. Woo, A. Aleshin and J. Y. Choe. (2013). "Crystal structure of a glucose/H⁺ symporter and its mechanism of action." Proc Natl Acad Sci U S A **110**(44): 17862-17867.

Jinek, M., K. Chylinski, I. Fonfara, M. Hauer, J. A. Doudna and E. Charpentier. (2012). "A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity." Science **337**(6096): 816-821.

Jinek, M., F. Jiang, D. W. Taylor, S. H. Sternberg, E. Kaya, E. Ma, C. Anders, M. Hauer, K. Zhou, S. Lin, M. Kaplan, A. T. Iavarone, E. Charpentier, E. Nogales and J. A. Doudna. (2014). "Structures of Cas9 Endonucleases Reveal RNA-Mediated Conformational Activation." Science **343**(6176):1247997.

Kawai, S., W. Hashimoto and K. Murata. (2010). "Transformation of *Saccharomyces cerevisiae* and other fungi: methods and possible underlying mechanism." Bioeng Bugs **1**(6): 395-403.

Ke, A., F. Ding, J. D. Batchelor and J. A. Doudna. (2007). "Structural roles of monovalent cations in the HDV ribozyme." Structure **15**(3): 281-287.

Kerr, R. A. and R. F. Service (2005). "What can replace cheap oil--and when?" Science **309**(5731): 101.

Köhler, A. and E. Hurt (2007). "Exporting RNA from the nucleus to the cytoplasm." Nat Rev Mol Cell Biol **8**(10): 761-773.

Krugel, H., G. Fiedler, I Haupt, E. Sarfert and H. Simon. (1988). "Analysis of the nourseothricin-resistance gene (nat) of *Streptomyces noursei*." Gene **62**(2): 209-217.

Lee, M. E., A. Aswani, A. S. Han, C. J. Tomlin and J. E. Dueber. (2013). "Expression-level optimization of a multi-enzyme pathway in the absence of a high-throughput assay." Nucleic Acids Res **41**(22): 10668-10678.

Mali, P., K. M. Esvelt, and G. M. Church. (2013). "Cas9 as a versatile tool for engineering biology." Nat Methods **10**(10): 957-963.

Mali, P., L. Yang, K. M. Esvelt, J. Aach, M. Guell, J. E. DiCarlo, J. E. Norville and G. M. Church. (2013). "RNA-guided human genome engineering via Cas9." Science **339**(6121): 823-826.

Marck, C., R. Kachouri-Lafond, I. Lafontaine, E. Westhof, B. Dujon and H. Grosjean. (2006). "The RNA polymerase III-dependent family of genes in hemiascomycetes: comparative

RNomics, decoding strategies, transcription and evolutionary implications." Nucleic Acids Res **34**(6): 1816-1835.

Ness, F., F. Lavallée, D. Dubourdieu, M. Aigle and L. Dulau. (1993). "Identification of Yeast Strains Using the Polymerase Chain Reaction." J. Sci. Food. Agric **62**(1): 89-94.
DOI: 10.1002/jsfa.2740620113

Ovchinnikov, S., H. Kamisetty and D. Baker. (2014). "Robust and accurate prediction of residue-residue interactions across protein interfaces using evolutionary information." Elife **3**: e02030.

Rubin, E. M. (2008). "Genomics of cellulosic biofuels." Nature **454**(7206): 841-845.

Shalem, O., N. E. Sanjana, E. Hartenian, X. Shi, D. A. Scott, T. S. Mikkelsen, D. Heckl, B. L. Ebert, D. E. Root, J. G. Doench and F. Zhang. (2014). "Genome-scale CRISPR-Cas9 knockout screening in human cells." Science **343**(6166): 84-87.

Sternberg, S. H., S. Redding, M. Jinek, E. C. Greene and J. A. Doudna. (2014). "DNA interrogation by the CRISPR RNA-guided endonuclease Cas9." Nature **507**(7490): 62-67.

Storici, F., C. L. Durham, D. A. Gordenin and M. A. Resnick. (2003). "Chromosomal site-specific double-strand breaks are efficiently targeted for repair by oligonucleotides in yeast." Proc Natl Acad Sci U S A **100**(25): 14994-14999.

Sun, L., X. Zeng, C. Yan, X. Sun, X. Gong, Y. Rao and N. Yan. (2012). "Crystal structure of a bacterial homologue of glucose transporters GLUT1-4." Nature **490**(7420): 361-366.

Teste, M. A., M. Duquenne, J. M. François and J. L. Parrou. (2009). "Validation of reference genes for quantitative expression analysis by real-time RT-PCR in *Saccharomyces cerevisiae*." BMC Mol Biol **10**: 99.

Turner, N. J. (2009). "Directed evolution drives the next generation of biocatalysts." Nat Chem Biol **5**(8): 567-573.

van den Ent, F. and J. Löwe (2006). "RF cloning: a restriction-free method for inserting target genes into plasmids." J Biochem Biophys Methods **67**(1): 67-74.

Webb, C. H., N. J. Riccitelli, D. J. Ruminiski and A. Luptak. (2009). "Widespread occurrence of self-cleaving ribozymes." Science **326**(5955): 953.

Wingler, L. M. and V. W. Cornish. (2011). "Reiterative Recombination for the in vivo assembly of libraries of multigene pathways." Proc Natl Acad Sci U S A **108**(37): 15135-15140.

Yokobayashi, Y., R. Weiss and F. H. Arnold. (2002). "Directed evolution of a genetic circuit." Proc Natl Acad Sci U S A **99**(26): 16587-16591.

700
701 Zhou, H., J. S. Cheng, B. L. Wang, G. R. Fink and G. Stephanopoulos. (2012). "Xylose
702 isomerase overexpression along with engineering of the pentose phosphate pathway and
703 evolutionary engineering enable rapid xylose utilization and ethanol production by
704 *Saccharomyces cerevisiae*." Metab Eng **14**(6): 611-622.
705
706

707

Figure 1. Comparing noise in plasmid and genomic expression of two fluorescent proteins. Proteins mRuby2 (false-colored red) and Venus (false-colored green) were expressed in the same cell with a strong, P_{TDH3} promoter. **(A)** Fluorescent proteins expressed on two separate CEN plasmids; **(B)** in tandem on a single CEN plasmid; **(C)** integrated into two different loci (*LEU2* and *URA3*) in the *S. cerevisiae* genome; and **(D)** integrated in tandem at a single locus (*URA3*) in the genome. Each image was auto-exposed for both red and green channels, with yellow showing co-expression of mRuby2 and Venus. The variability in the relative expression of the two fluorescent proteins is reduced by moving from two plasmids to one, and the variability in total expression is reduced by moving to the genome. The difference between integrating into one or two loci in the genome is minimal.

Figure 2. The engineered CRISPRm platform. **(A)** Cas9 construct used for nuclear localization experiments. The *Streptococcus pyogenes* Cas9 protein was tagged with a C-terminal nuclear localization motif and a green fluorescent protein (GFP) (green). For genome editing experiments, the *Streptococcus pyogenes* Cas9 protein was tagged with a C-terminal nuclear localization motif and a Histidine affinity tag (grey). **(B)** Cellular localization of Cas9-GFP in exponentially growing *S. cerevisiae* cells. The Cas9-GFP protein was expressed from the *TDH3* promoter in this experiment. Left, bright field image; right fluorescence microscopy. **(C)** Growth profiles of yeast expressing Cas9 from a strong promoter *P_{TDH3}* (black) or a weaker promoter *P_{RNR2}* (blue) relative to wild type (red). **(D)** The mature sgRNA contains a 5' hepatitis delta virus (HDV) ribozyme (δ R, brown), 20mer target sequence (green), sgRNA (black) and RNA polymerase III terminator (red). The RNA polymerase III promoter tRNA (blue) is catalytically removed by the HDV ribozyme (red arrow). **(E)** Schematic of yeast Cas9 targeting. Cas9 and sgRNA are expressed from a single plasmid, form a complex, and cleave targeted genomic DNA, which is repaired using a barcoded oligonucleotide. **(F)** The linear barcoded repair DNA molecule. Each repair DNA contains a 5' TAA stop codon (gold), a forward primer sequence (green), a unique molecular barcode (grey), and a 3' reverse primer (green) (Giaever et al. 2002). Barcodes are amplified using a forward primer that contains 50bp of homology (blue) to the genome targeting site and a reverse primer that contains 50bp of homology to the genome targeting site. The 50bp of genomic targeting sequence are each 10bp proximal to the PAM motif, resulting in a 20nt deletion and barcode oligonucleotide integration.

Figure 3. CRISPRm barcode insertion in yeast cells. **(A)** Targeting efficiency at the *URA3* locus in diploid S288C yeast using RNA polymerase III promoters (x axis) to drive the expression of the sgRNA. **(B)** Targeting efficiency measured across 11 loci in 10 genes in diploid cells of yeast strain S288C, using the tRNA^{Tyr} promoter. **(C)** Single fragment barcode integration (blue) and three-fragment Nat^R cassette integration (yellow) efficiency in S288C diploid and ATCC4124 polyploid strains. For each experiment the promoter and strain are indicated as promoter-strain (e.g. SNR52-S288C). **(D)** Efficiency of multiplex insertion of barcoded DNA in diploid yeast cells with the 5' HDV ribozyme (black) and without the 5' HDV ribozyme (red). Triplex targeting without the 5' HDV ribozyme was not tested. The tRNA^{Tyr} promoter was used in these experiments. **(E)** The addition of a 5' HDV ribozyme increases the intracellular levels of sgRNA by six-fold. The RT-qPCR experiments were carried out in biological triplicate, with the mean and standard deviation shown. **(F)** Efficiency of targeting one (*URA3*), two (*URA3*, *LYP1*) and three (*URA3*, *LYP1* and *COX10*) in haploid S288C yeast cells. The tRNA^{Tyr} promoter was used for sgRNA expression.

Figure 4. CRISPRm mediated insertion and evolution of chromosomal DNA libraries for *in vivo* protein engineering. **(A).** Utilization of cellobiose in CRISPRm-engineered diploid yeast strains. S288C wild type *cdt-1*⁻ (black), *cdt-1* (blue), *cdt-1*^{Q45H/F262Y/F533Y} (indicated as *cdt-1*^{F262Y*} on the figure, grey), *cdt-1*^{N209S/I354N/S360P/T406S/W531L} (indicated as *cdt-1*^{N209S*} on the figure, green) and *cdt-1*^{N209S+Q45H/F262Y/F533Y} (indicated as *cdt-1*^{N209S+F262Y*} on the figure, red). **(B)** Location of mutations at conserved sites in the evolved CDT-1 transporter structure. The mutated residues are colored magenta in the top figure, and are mapped onto the *E. coli* XylE transporter in the outward-facing configuration bound to glucose (upper panels and lower left, PDB entry 4GBZ), and onto the *S. epidermidis* GlcP transporter in the inward-facing configuration (lower right, PDB entry 4LDS). Amino acids in parentheses are the sequences in XylE or GlcP. **(C)** Fermentation of cellobiose by wild-type *cdt-1* expressed from a chromosomally-integrated copy in diploid S288C yeast. Cellobiose is indicated as G2, ethanol as EtOH. The rate of cellobiose consumption was 0.13 g L⁻¹ hr⁻¹. **(D)** Fermentation of cellobiose by mutant versions of *cdt-1* expressed from chromosomally-integrated copies. Glucose consumption (grey) was identical in both strains. The rate of cellobiose consumption for both strains was over 2.0 g L⁻¹ hr⁻¹. In panels **C** and **D**, values and error bars represent the means and standard deviations of three independent biological replicates.

780 **Supplementary Data**

781

782 **Supplementary file 1A.** CRISPR-Cas screening results

783 **Supplementary file 1B.** Potential off-target mutations identified by whole genome

784 sequencing

785 **Supplementary file 1C.** RNA polymerase III promoter sequences used to express sgRNAs

786 **Supplementary file 1D.** Guide sequences used in this study

787

788 **Supplementary file 2A.** pCAS – Tyrosine - sgRNA-LYP1

789 **Supplementary file 2B.** pOR1.1

790 **Supplementary file 2C.** sgRNA without HDV ribozyme

791 **Supplementary file 2D.** sgRNA with HDV ribozyme

792

793 **Supplementary file 3.** Custom perl script for Cas9 target identification in S288C genome.

794 **Supplementary file 4.** Custom R script for yeast genome analysis.

795



796

797



two loci






one locus







plasmid






genome



A**B****C****D****E****F**

A**B****C****D****E****F**

A**B****C****D**